Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 4/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | GRM8 | O00222 | 1/20 | 0.30 |
| ▸ | GRM6 | O15303 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16819017 | 0.79 | TSHR (0.30) | — | |
| SCHEMBL18358200 | 0.78 | OPRM1 (0.34) | MEN1KMT2AKDM4EALOX15 | |
| SCHEMBL20107144 | 0.78 | OPRM1 (0.34) | MEN1KMT2AKDM4EALOX15 | |
| SCHEMBL18358210 | 0.78 | OPRM1 (0.34) | MEN1KMT2AKDM4EALOX15 | |
| SCHEMBL18358230 | 0.78 | OPRM1 (0.34) | MEN1KMT2AKDM4EALOX15 | |
| SCHEMBL21048292 | 0.75 | PPM1B (0.32) | — | |
| SCHEMBL25331473 | 0.71 | APLNR (0.34) | CYP2C19 | |
| SCHEMBL31530488 | 0.71 | APLNR (0.34) | CYP2C19 | |
| SCHEMBL25331476 | 0.71 | APLNR (0.34) | CYP2C19 | |
| SCHEMBL25907708 | 0.71 | GRM2 (0.42) | GRM4GRM8GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087592-A1 | ENZYMATIC PROCESSES FOR THE PREPARATION OF (±)-2-(DIFLUOROMETHYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID AND (±)-2-(VINYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID | ABBVIE INC. | 2021-03-25 | — | — | US | disclosed |
| CN-110461812-A | Enzymatic process for the preparation of (+ -) -2- (difluoromethyl) -1- (alkoxycarbonyl) -cyclopropanecarboxylic acid and (+ -) -2- (vinyl) -1- (alkoxycarbonyl) -cyclopropanecarboxylic acid | ABBVIE INC | 2019-11-15 | — | — | CN | disclosed |
| US-10316338-B1 | Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid | ABB VIE INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180258451-A1 | ENZYMATIC PROCESSES FOR THE PREPARATION OF (±)-2-(DIFLUOROMETHYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID AND (±)-2-(VINYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID | ABBVIE INC. | 2018-09-13 | — | — | US | disclosed |
| WO-2018144681-A1 | ENZYMATIC PROCESSES FOR THE PREPARATION OF (±)-2-(DIFLUOROMETHYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID AND (±)-2-(VINYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID | ABBVIE INC. (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087592-A1 | ENZYMATIC PROCESSES FOR THE PREPARATION OF (±)-2-(DIFLUOROMETHYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID AND (±)-2-(VINYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC ACID | CTRL, DNPEP, CPN1 | GRM4 3667/4885ALDH1A1 533/4885CYP1A2 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.